NCT03775525View on ClinicalTrials.gov

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

May 31, 2023

Study Completion Date

December 31, 2023

Conditions
Advanced CancerGastric CancerBreast CancerPancreatic CancerProstate Cancer MetastaticColo-rectal CancerSolid TumorSolid CarcinomaSolid Carcinoma of StomachCancer of StomachLymphomaSarcomaCutaneous T Cell LymphomaHead and Neck Squamous Cell CarcinomaBasal Cell CarcinomaCutaneous T-cell LymphomaCutaneous Squamous Cell Carcinoma
Interventions
DRUG

GZ17-6.02

Super enhancer Inhibition

DRUG

Capecitabine

antimetabolite

Trial Locations (4)

70121

Ochsner Clinic Foundation, New Orleans

75246

Baylor Charles A. Sammons Cancer Center, Dallas

85258

HonorHealth Research Institute, Scottsdale

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Translational Drug Development

OTHER

lead

Genzada Pharmaceuticals USA, Inc.

INDUSTRY

NCT03775525 - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | Biotech Hunter | Biotech Hunter